GLP-1 meds like Ozempic, Wegovy may lower cancer risk

CTV News July 7, 2024, 03:00 PM UTC

Summary: A study suggests GLP-1 medications like Ozempic and Wegovy may lower the risk of certain cancers. Overweight individuals face a higher risk of 13 types of cancer, with 40% of new diagnoses linked to excess weight. GLP-1 treatment reduced the risk of 10 obesity-associated cancers, including gallbladder, pancreatic, and liver cancer. The study analyzed data from 1.7 million people with type 2 diabetes. Further research is needed on the relationship between weight loss and cancer risk reduction.

Full article

Article metrics
Significance5.3
Scale7.0
Magnitude8.0
Novelty6.0
Actionability5.0
Immediacy5.0
Positivity8.0
Probability7.0
Credibility7.8

Timeline:

  1. [2.5]
    Semaglutide may pose risk of vision loss: Study urges caution (Business Standard)
    1d
    Source
  2. [4.7]
    Ozempic improves heart and kidney health for diabetes patients (Sydney Morning Herald)
    2d
    Source
  3. [4.9]
    Semaglutide (Ozempic) may reduce dementia risk and nicotine cravings (Neuroscience News)
    3d
    Source
  4. [3.2]
    Ozempic linked to lower dementia risk, nicotine use in study (The Globe and Mail)
    3d
    Source
  5. [3.2]
    Ozempic linked to lower dementia risk, nicotine use - study (The Straits Times)
    3d
    Source
  6. [3.9]
    Antidiabetic drugs linked to lower dementia risk in T2DM (News-Medical.Net)
    3d
    Source
  7. [4.0]
    Ozempic linked to lower dementia rate in Oxford study (BNN Bloomberg)
    3d
    Source
  8. [3.5]
    Ozempic and similar drugs may lower cancer risks (Forbes Australia)
    3d
    Source
  9. [3.3]
    GLP-1 agonists lower dementia risk for diabetes patients (PsyPost)
    3d
    Source
  10. [3.9]
    Weight-loss jabs lower cancer risk compared to insulin - study (The Conversation)
    4d
    Source
  11. [4.7]
    GLP-1 agonists reduce cancer risk in type 2 diabetes (Inside Precision Medicine)
    5d
    Source
  12. [3.4]
    GLP-1s reduce cancer risk in type 2 diabetes patients (PMLiVE)
    5d
    Source
  13. [3.9]
    GLP-1 drugs linked to lower cancer risks in diabetes patients (Ars Technica)
    6d
    Source
  14. [3.5]
    Semaglutide linked to rare eye disease causing vision loss (ScienceAlert)
    6d
    Source
  15. [2.2]
    Semaglutide linked to higher risk of NAION in study (The Express Tribune)
    7d
    Source
  16. [2.5]
    Semaglutide (Ozempic) linked to increased risk of blindness (Insight)
    7d
    Source
  17. [5.5]
    GLP-1 agonists like Ozempic lower cancer risks in study (ScienceAlert)
    7d

  18. [4.4]
    GLP-1 diabetes drugs reduce cancer risk, study finds (The Manila Times)
    9d
    Source
  19. [5.0]
    GLP-1 medications may lower risk of certain cancers (CNN)
    9d

  20. [2.2]
    GLP-1s lower risk of 10 obesity-related cancers in diabetes (Medpage Today)
    10d
    Source
  21. [5.2]
    GLP-1 drugs like Ozempic may reduce cancer risk (Quartz)
    10d

  22. [5.1]
    GLP-1 treatments reduce cancer risk in diabetes patients (GMA News Online)
    10d

  23. [5.1]
    GLP-1 drugs reduce cancer risks for diabetes patients (Finimize)
    10d

  24. [1.3]
    Weight loss drugs linked to rare eye condition risk (India TV News)
    10d
    Source
  25. [2.9]
    Weight-loss drugs may increase risk of rare blindness (Firstpost)
    11d
    Source
  26. [3.2]
    Novo Nordisk weight loss drugs linked to rare eye condition (CNBC)
    11d
    Source
  27. [3.3]
    Ozempic linked to rare blindness cases in study (Business Insider)
    12d
    Source
  28. [3.2]
    Wegovy, Ozempic linked to sight-threatening eye disorder in study (GMA News Online)
    12d
    Source
  29. [3.2]
    Weight-loss jabs linked to potential blindness risk in study (The Guardian)
    12d
    Source
  30. [3.4]
    Weight loss and diabetes drugs linked to rare blindness risk (CNN)
    12d
    Source